BioLife Solutions to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019

On October 31, 2019 BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, ("BioLife" or the "Company"), reported that the Company’s third quarter 2019 financial results will be released after market close on Tuesday, November 12, 2019, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon (Press release, BioLife Solutions, OCT 31, 2019, View Source [SID1234550149]). Management will provide an overview of the Company’s financial results and a general business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the webcast, log on to the Investor Relations page of the BioLife Solutions website at www.biolifesolutions.com/earnings. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 7207519. A webcast replay will be available approximately two hours after the call and will be archived on www.biolifesolutions.com for 90 days.

Medpace Holdings, Inc. to Present at Credit Suisse Healthcare Conference

On October 31, 2019 Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") reported that it will present at the following investor conference in November (Press release, Medpace, OCT 31, 2019, View Source [SID1234550148]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Credit Suisse Healthcare Conference
Location: Scottsdale, AZ
Date: Tuesday, November 12, 2019
Presentation: 8:35 a.m. MT (10:35 a.m. ET)
Speakers: Dr. August Troendle, President & Chief Executive Officer, and Jesse Geiger, Chief Financial Officer & Chief Operating Officer, Laboratory Operations

A live webcast of the presentation will be accessible through the "Investors" section of the Company’s website at www.medpace.com and will be available for replay following the event.

SignPath Pharma, Inc. Announces an Out-license Agreement of Its CorreQTTM Technology for Mitigation of QT Prolongation with Rain Therapeutics Inc.

On October 31, 2019 SignPath Pharma (Salt Lake City UT) reported the first commercial out-license of its proprietary CorreQT technology platform (Press release, SignPath Pharma, OCT 31, 2019, View Source [SID1234550147]). SignPath entered into an agreement with Rain Therapeutics (Newark CA), which licenses SignPath’s CorreQT technology for use in conjunction with Rain’s proprietary lead compound, Tarlox (tarloxotinib,) a potent pan-ErbB inhibitor in development as a treatment in various cancer indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SignPath’s CorreQT technology is a novel, patented, platform that eliminates cardiac arrhythmia (QT prolongation) which is a common side effect of many drugs. The CorreQT technology has been shown to effectively eliminate these cardiac side effects without negatively impacting the efficacy or pharmacokinetics of the drug target.

"We’re excited to embark on a partnership to evaluate Signpath’s CorreQT technology," said Avanish Vellanki, chairman and chief executive officer of Rain Therapeutics. "Initial non-clinical data have been very encouraging."

The Rain/SignPath license agreement provides for payments of up to $78 million upon achievement of development and commercial milestones, along with royalties on commercial sales of Tarlox products incorporating SignPath’s CorreQT technology.

"We anticipate that this will be the first of many commercial applications of our CorreQT technology. Cardiac arrhythmia is one of the biggest obstacles to drug safety, and our technology provides a solution for creating heart safe drugs by eliminating their pro-arrhythmic side effects," said Kai Larson, CEO of SignPath. "The CorreQT technology has been successfully tested with 40 different pro-arrhythmic drug targets, including anti-depressants, antibiotics, anticancer, and other drug classes, completely eliminating QT prolongation in all of these drug targets. We believe that SignPath’s technology will become the preferred solution for addressing cardiac arrhythmia for both approved drugs and those in development."

SignPath Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of heart safe drugs for the treatment of serious diseases. The first such drug, LipoCurcTM, an anti-cancer compound, has successfully completed Phase I human clinical trials. Further clinical trials with LipoCurcTM and SPP4040, SignPath’s proprietary adjuvant for mitigating cardio-toxicity, are planned for 2020.

Invenra Announces Expansion of Collaboration with Exelixis

On October 31, 2019 Invenra Inc. reported that it has expanded its collaboration with Exelixis, Inc. (Nasdaq: EXEL) (Press release, Invenra, OCT 31, 2019, View Source [SID1234550146]). Exelixis and Invenra had entered into a collaboration on May 2nd, 2018 to discover and develop multispecific antibodies through the use of Invenra’s B-BodyTM technology platform. The new collaboration will continue to use the Invenra antibody discovery capabilities to generate additional biologics-based programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The expanded collaboration speaks to the strength and early success of the initial collaboration between Exelixis and Invenra," said Bonnie Hammer, Ph.D., Vice President of Research and Development of Invenra. "We are excited to continue to work with the Exelixis team. Both teams have demonstrated the desire to generate best-in-class therapeutics, and this expanded collaboration enables us to continue generating novel candidates for the Exelixis pipeline."

The Mary Kay Foundation Awards $3.1 Million in Cancer Research and Domestic Violence Shelter Grants

On October 31, 2019 The Mary Kay FoundationSM reported that awarded over $3 million in cancer research and domestic violence shelter grants around the country (Press release, The Mary Kay Foundation, OCT 31, 2019, View Source [SID1234550145]). The Mary Kay Foundation was established in 1996 with the overarching purpose of eliminating cancers affecting women. In 2000, The Foundation expanded to include ending domestic violence as part of its mission.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

100 domestic violence shelters across the country, including Puerto Rico and the Virgin Islands, have been awarded $20,000 each, totaling $2 million. The Foundation is committed to funding the life-saving work of women’s shelters, and the annual shelter grant program has helped finance critical needs including emergency shelter, transitional housing, counseling and legal aid. All of these resources support women and children as they seek refuge and relief on their journey to an abuse-free life.

While a majority of domestic violence shelter grant recipients use the unrestricted funds for necessary operating expenses, others will complete repairs and facility renovations or add programs and resources based on the unique needs of their shelter and the clients they serve. Margie’s Haven House in Heber Springs, Arkansas, for example, plans to use their grant on a vehicle to help transport their clients to safety. In Decatur/Macon County, Illinois, and four surrounding counties, Dove, Inc. funds will be applied to the expense of increasing security to the entrance of their shelter. The exterior shelter door will be replaced with a fiberglass door, and an interior wall and an additional door will be added at the reception area.

Nearly 400,000 women and their families will receive domestic violence support services and free resources through the 100 agencies awarded.

After reviewing more than 70 applications, The Mary Kay Foundation Research Review Committee awarded $100,000 grants to 11 cancer research institutions across the country, totaling $1.1 million. This year’s grant recipients include the following leading research institutions:

Albert Einstein College of Medicine
Case Western Reserve University School of Medicine
Georgetown University
Michigan State University
University of California, San Francisco
University of Kansas Medical Center
University of Notre Dame
University of Utah
UT Southwestern Medical Center
Vanderbilt University Medical Center
Weill Cornell Medicine
"At The Mary Kay Foundation, we believe in helping women improve their circumstances and live their best lives," said Michael Lunceford, President of The Mary Kay Foundation Board of Directors. "Our Foundation seeks to do that in two critical ways: fund breakthrough research in our mission to eliminate cancers affecting women, and provide resources to domestic violence shelters across the country so they can aid survivors."

The Foundation’s 2019 cancer research grants will support many innovative studies. At Case Western Reserve University School of Medicine, Dr. Stefanie Avril is conducting groundbreaking research to harness the body’s immune system to eradicate breast cancer. At Georgetown University, Assistant Professor Dr. Cecil Han will utilize the grant to further her research on how changing metabolic pathways impacts the rapid growth and development of ovarian cancer cells in early stage. And at the University of Kansas Medical Center, Dr. Priyanka Sharma will use her 15 years of experience to research efforts on Triple Negative Breast Cancer, Novel Targeted Agents, Breast Cancer Genetics and Neoadjuvant Chemotherapy with the hopes of finding successful treatments for some of the most aggressive forms of breast cancer.

"We’ve seen previous grants lead to innovative breakthroughs in the study of breast, uterine, cervical and ovarian cancers, and are excited to see the research contributions of this year’s recipients," said Lunceford. "By continuing support for these scientists and institutions, we know we are continuing to better the lives of women everywhere."

Over the course of more than two decades, The Mary Kay FoundationSM has awarded more than $80 million to women’s shelters and domestic violence service providers, as well as cancer research programs and related causes throughout the United States.